Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. [Review]
Citation: Critical Care Medicine. 40(11):2945-53, 2012 Nov.PMID: 22971586Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Journal Article | Meta-Analysis | ReviewSubject headings: *Adrenal Insufficiency/ci [Chemically Induced] | *Anesthetics, Intravenous/ae [Adverse Effects] | *Etomidate/ae [Adverse Effects] | *Sepsis/co [Complications] | *Sepsis/mo [Mortality] | Aged | Aged, 80 and over | Female | Humans | Male | Middle Aged | Qualitative Research | Randomized Controlled Trials as TopicYear: 2012Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006ISSN:- 0090-3493
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 22971586 | Available | 22971586 |
Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
CONCLUSIONS: Administration of etomidate for rapid sequence intubation is associated with higher rates of adrenal insufficiency and mortality in patients with sepsis.
DESIGN: A systematic review of randomized controlled trials and observational studies with meta-analysis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We conducted a systematic review of randomized controlled trials and observational studies with meta-analysis assessing the effects of etomidate on adrenal insufficiency and all-cause mortality published between January 1950 and February 2012. We only examined studies including septic patients. All-cause mortality served as our primary end point, whereas the prevalence of adrenal insufficiency was our secondary end point. Adrenal insufficiency was determined using a cosyntropin stimulation test in all studies. We used a random effects model for analysis; heterogeneity was assessed with the I statistic. Publication bias was evaluated with Begg's test. Five studies were identified that assessed mortality in those who received etomidate. A total of 865 subjects were included. Subjects who received etomidate were more likely to die (pooled relative risk 1.20; 95% confidence interval 1.02-1.42; Q statistic, 4.20; I2 statistic, 4.9%). Seven studies addressed the development of adrenal suppression associated with the administration of etomidate; 1,303 subjects were included. Etomidate administration increased the likelihood of developing adrenal insufficiency (pooled relative risk 1.33; 95% confidence interval 1.22-1.46; Q statistic, 10.7; I2 statistic, 43.9%).
OBJECTIVE: To evaluate the effects of single-dose etomidate on the adrenal axis and mortality in patients with severe sepsis and septic shock.
SETTING: Literature search of EMBASE, Medline, Cochrane Database, and Evidence-Based Medical Reviews.
SUBJECTS: Sepsis patients who received etomidate for rapid sequence intubation.
English